Related Experiment Video
Updated: Jul 20, 2026
05:00
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
Published on: April 1, 2019
Pharmacological treatments for thyroid eye disease
Sara P Modjtahedi1, Bobeck S Modjtahedi, Ahmad M Mansury
1Division of Orbital and Ophthalmic Plastic and Reconstructive Surgery, and the Department of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA 90095-7006, USA.
Drugs
|September 19, 2006
Summary
Thyroid eye disease (TED) management varies by severity. While mild cases benefit from supportive care, severe TED requires aggressive treatments like corticosteroids, with promising research into antioxidants and cytokine antagonists.
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Thyroid eye disease (TED) frequently impacts patients with Graves' disease, leading to considerable ophthalmic complications.
- Management strategies for TED range from supportive care for mild cases to aggressive interventions for severe presentations.
Purpose of the Study:
- To review current treatment modalities for thyroid eye disease (TED).
- To discuss the efficacy of various pharmacological and surgical interventions.
- To highlight emerging therapeutic avenues for TED management.
Main Methods:
- Literature review of current treatment options for thyroid eye disease.
- Analysis of the role of corticosteroids and immunosuppressive agents.
- Evaluation of novel therapeutic agents, including antioxidants and cytokine antagonists.
Main Results:
- Corticosteroids are the primary pharmacological treatment for active inflammatory TED.
- Combination therapy with other immunosuppressants may benefit corticosteroid-resistant cases.
- Somatostatin analogues show limited clinical benefit, while antioxidants and cytokine antagonists present encouraging preliminary findings.
Conclusions:
- Treatment for thyroid eye disease (TED) must be tailored to disease severity and inflammatory activity.
- Corticosteroids and immunosuppressants remain mainstays for moderate to severe TED.
- Ongoing research into novel agents like antioxidants and cytokine antagonists offers future therapeutic potential for TED.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...